Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Find therapies in clinical trials near you – page 16

recruiting
3 977
countries
28
conditions
2 105

1 112 trials match your criteria

Ischaemic stroke

Recruiting

Study of alteplase and tenecteplase for intravenous thrombolysis in patients with ischemic stroke who are taking direct oral anticoagulants

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Alteplase

Dry age-related macular degeneration

Recruiting

Study of ONL1204 eye injections to slow vision loss in patients with age-related macular degeneration and geographic atrophy

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Xelafaslatide

B-cell lymphoma recurrent+1

Recruiting

Study of drug combination therapy in children and adolescents with relapsed or refractory B-cell non-Hodgkin lymphoma using odronextamab, loncastuximab tesirine and rituximab

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years
  • Substances:Carboplatin

Acute myocardial infarction

Recruiting

Study of ziltivekimab compared to placebo in patients with acute heart attack to evaluate its effects on coronary artery plaque reduction

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Ziltivekimab

Cardiomyopathy

Recruiting

Study of Nucresiran in Adults with Transthyretin Amyloidosis with Cardiomyopathy to Evaluate its Effects on Survival and Heart Problems

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years

Non-small cell lung cancer+5

Recruiting

Study of cemiplimab treatment after surgery in patients with stage II-IIIA non-small cell lung cancer who have not received chemotherapy and have PD-L1 expression of 1% or higher

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Cemiplimab

Arteriosclerosis

Recruiting

Long-term safety study of pelacarsen in patients with atherosclerotic cardiovascular disease who completed the Lp(a)HORIZON trial

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Pelacarsen

Plasma cell myeloma

Recruiting

Study comparing daratumumab, lenalidomide and dexamethasone followed by linvoseltamab versus continued initial treatment in newly diagnosed multiple myeloma patients

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Daratumumab

Squamous cell carcinoma of head and neck

Recruiting

Study of ficerafusp alfa and pembrolizumab as first treatment for patients with PD-L1-positive recurrent or metastatic head and neck cancer

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab

Chronic obstructive pulmonary disease

Recruiting

Study of dupilumab injections to reduce airway inflammation in adults aged 40-85 with chronic obstructive pulmonary disease

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Dupilumab

Non-small cell lung cancer

Recruiting

Study of zoldonrasib with daraxonrasib, pembrolizumab and chemotherapy in patients with RAS G12D-mutant non-small cell lung cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin

IgA nephropathy

Recruiting

Study of Mezagitamab in Adults with Primary IgA Nephropathy (Berger's Disease) to Reduce Protein in Urine

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years

Explore other searches

Helpful resources

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.